HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ECHA Supporting Efforts To Speed Disinfectants To European Market

Executive Summary

The European Chemicals Agency is working to develop a centralized, expedited authorization process to increase the availability of disinfectants to consumers and healthcare professionals fighting the novel coronavirus. Meanwhile, the ECHA encourages companies to work with national authorities on single-market applications for derogations under the Biocidal Products Regulation to speed up production.

You may also be interested in...



Ulta On Q1 COVID-19 Impact; ‘Illegal And Ineffective’ Hand Sanitizers In Europe; More Cosmetics News

Ulta Beauty says sales are roughly flat in the first 180 stores it reopened following the COVID-19 shutdown, which dragged down its net sales roughly 33% in the fiscal 2020 first quarter. More cosmetics news in brief.

COVID-19 Beauty News In Brief: Ulta Announces Furloughs; ECHA Postpones New Dossier Checks; More

Quick looks at how beauty and personal-care industry stakeholders are responding to the pandemic, from temporary furloughs to corporate citizenship investments and regulatory accommodations for beleaguered businesses.

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149851

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel